Focus:
Venture Capital
-
24 July 2020
Investing in late-stage companies: Forbion closes Growth Fund at €185m
Forbion has closed its new Growth Opportunities Fund at €185m, but it is hoping to raise a further €65m before the fund is completed this year. This fund will invest...
-
22 July 2020
Exploring the promise of DUBs: Mission teams up with Pfizer
Pfizer Ventures has expanded its relationship with DUB-focused Mission Therapeutics by leading a $15m funding round. The pharma giant’s core company has also signed a scientific partnership to validate promising...
-
20 July 2020
Off-the-shelf NK cell therapies: Artiva closes $78m Series A round
Artiva is working on bringing off-the-shelf NK cell therapies to cancer patients, supported by the manufacturing expertise of GC LabCell. To fund Artiva’s progression of three lead candidates to clinical...
-
13 July 2020
Autobahn Labs: virtual incubator launches with a focus on academia
Autobahn Labs has been launched by Samsara BioCaptial, KCK and Evotec. Purposefully created to invest at earlier stages of development than traditional venture firms, in universities directly and globally because...
-
10 July 2020
Eir Ventures launches to unlock the potential of the Nordics
Supported by three prestigious investment companies and the EU's EIF, Eir Ventures is a Nordic-based venture company with €76m to invest in promising ideas from regional universities and incubators. How...
-
2 July 2020
Ona’s €30m Series A round: directly targeting metastasis in cancer
Slightly over a year since its launch, Ona has raised €30m in a Series A round. This funding will be used to advance the company’s work on preventing and treating...
-
29 June 2020
C4T raises $170m for human trials of degrader drugs
C4T has raised $170m from a Series B round and venture debt funding. This influx of capital will be used to move its four lead degrader drugs into clinical trials...
-
16 June 2020
Novo Ventures gives the nod to NodThera’s inflammatory disease innovations
Focused on targeting the source of chronic inflammation, NodThera has completed a $55m Series B round, which was led by Novo Ventures. What makes NodThera an attractive proposition to investors...
-
10 June 2020
Spotlight on BaseLaunch: fostering innovative start-ups in Basel
Supported by the strong biotech ecosystem in the Basel area, life sciences incubator and accelerator BaseLaunch has a perfect record in supporting its start-ups to reach Series A financing rounds....
-
4 June 2020
Promise of AI in drug discovery: Exscientia raises $60m in Series C round
Novo Holdings led AI drug discovery-focused Exscientia’s recent $60m Series C round. In a strong vote of confidence, three previous investors - of which two are also development partners –...